Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib

@inproceedings{Moryoussef2015ReversibleSI,
  title={Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib},
  author={Fr{\'e}d{\'e}rick Moryoussef and Marion Dhooge and Julien Volet and Coralie Barbe and Catherine Br{\'e}zault and Christine Hoeffel and Romain Coriat and Olivier Bouch{\'e}},
  booktitle={Journal of cachexia, sarcopenia and muscle},
  year={2015}
}
BACKGROUND Imatinib is a long-term, oral, targeted therapy for high-risk resected and advanced gastrointestinal stromal tumours (GIST). It is known that sarcopenia affects prognosis and treatment tolerance in patients with various solid cancers. We analysed lumbar skeletal muscle index changes in imatinib-treated GIST patients. Imatinib tolerance was also assessed to evaluate the influence of pre-treatment sarcopenia. METHODS Thirty-one patients with advanced (n = 16) or high-risk resected (n… CONTINUE READING